A Phase 1, Open-Label, Dose-Escalation Study of AQ4N Administered Intravenously in Patients With Advanced Malignancies
This study is for people who have advanced cancer for which standard chemotherapy did not
work or for which there are no reliably, effective treatments.
AQ4N is an experimental chemotherapy that is thought to target tumor areas with low oxygen
content and low blood supply; tumor areas that are usually the most resistant to standard
chemotherapy and radiation treatment. AQ4N may be beneficial in cancer treatment by
interfering with a protein that is required for cells to grow and divide, causing tumors to
die or to delay their growth.
All patients in this study will receive AQ4N. The dose will be increased for each new
patient or group of patients until the maximum tolerated dose is reached.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
|Weiler Hospital of Albert Einstein College of Medicine||Bronx, New York 10461|
|Cancer Therapy & Research Center / Institute for Drug Development||San Antonio, Texas 78229|